Tango Therapeutics, Inc. (TNGX)
20.62
+0.06
(+0.29%)
USD |
NASDAQ |
May 18, 13:20
Tango Therapeutics Research and Development Expense (Quarterly) : 33.07M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Revolution Medicines, Inc. | 341.62M |
| Kodiak Sciences, Inc. | 48.55M |
| Recursion Pharmaceuticals, Inc. | 75.20M |
| Hims & Hers Health, Inc. | 46.94M |
| Erasca, Inc. | 27.26M |